The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

Abstract Background and Hypothesis There is limited evidence to guide the approaches to
clozapine treatment. Accordingly, an international initiative was undertaken with the aim of …

Introduction Maintenance antipsychotic treatment improves multiple outcomes in people with
schizophrenia. These benefits are challenged by medication nonadherence, which is a …

The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for
psychiatry. The authors review the history, classification, indications, mechanism, efficacy …

Objective: The incidence of neuroleptic malignant syndrome (NMS), a rare, potentially fatal
adverse effect of antipsychotics, among children and youth is unknown. This cohort study …

Objectives: Co-occurring substance use disorders (SUDs) among individuals with
schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with …

Background Although clozapine is effective for treatment-resistant schizophrenia (TRS), the
rate of clozapine prescription is still low. Whereas antipsychotic monotherapy is …

Objective: Switching of antipsychotic medications, which are used for many psychiatric
conditions, is common. However, reasons and clinical documentation of such switches have …

Introduction Antipsychotics are the foundation of pharmacologic treatment for schizophrenia.
There are many oral antipsychotics available and given that these medications are generally …

Approximately 8% of patients with schizophrenia are diagnosed before age 18, and 18%
experience their first symptoms before age 18. This narrative review explores the …